Intrauterine Device – Levo­nor­gestrel 52 mg [Design Issues]

posted by marianna.macera – Brazil, 2021-07-02 16:55 (325 d 02:49 ago) – Posting: # 22453
Views: 671

Dear Relaxation,

I appreciated your answer, thank you.
There is Besides " FDA Draft Guidance on Levonorgestrel", We used data from the article: "Comparative pharmacokinetic analysis of levonorgestrel-releasing intrauterine systems and levonorgestrel-containing contraceptives with oral or subdermal administration route" Hofmann et. al, 2020.
But the point still the number of subjects in this BE/BA study, because in this case, parallel design needs an intra+inter CV%. But in a scientific literature review, we don't find something like that. A suggestion about mitigating the error in subject number determination?

Best regards,

Complete thread:

UA Flag
Activity
 Admin contact
22,092 posts in 4,630 threads, 1,567 registered users;
online 12 (0 registered, 12 guests [including 10 identified bots]).
Forum time: Monday 19:44 CEST (Europe/Vienna)

There is no adequate defense, except stupidity,
against the impact of a new idea.    Percy Williams Bridgman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5